REFRACTORY MALIGNANT SOLID NEOPLASM
Clinical trials for REFRACTORY MALIGNANT SOLID NEOPLASM explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY MALIGNANT SOLID NEOPLASM trials appear
Sign up with your email to follow new studies for REFRACTORY MALIGNANT SOLID NEOPLASM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Triple-Drug attack on advanced cancers enters human trials
Disease control Recruiting nowThis study tests whether combining three drugs (axatilimab, retifanlimab, and paclitaxel) is safe and works against advanced or metastatic solid tumors. About 38 adults with tumors that have spread or come back will receive the combination. The goal is to find the best dose and s…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated May 26, 2026 04:10 UTC
-
New combo therapy targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests two experimental drugs, ZEN003694 and entinostat, in people with advanced or treatment-resistant solid tumors, including pancreatic cancer. The goal is to find the safest dose and see if the combination can shrink tumors. About 49 participants will take part in t…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:09 UTC
-
New hope for young cancer patients: experimental drug targets tough tumors
Disease control Recruiting nowThis study tests a drug called tegavivint in children, teens, and young adults (ages 1 to 30) whose solid tumors have returned or not responded to standard therapy. The drug works by blocking a key signal that tells cancer cells to grow. The trial aims to find the safest dose, un…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated May 26, 2026 04:09 UTC
-
New hope for kids with tough cancers: two drug combos enter trial
Disease control Recruiting nowThis study is for children and young adults (ages 1 to 30) whose solid tumors have come back or never fully went away. It tests two different drug combinations that damage cancer cell DNA to kill the tumor. The goal is to find the safest dose and see if the tumors shrink or disap…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated May 26, 2026 04:05 UTC
-
New drug MTI-301 targets Cancer's fuel supply in early trial
Disease control Recruiting nowThis early-stage trial tests a new drug called MTI-301 in about 42 adults with advanced solid cancers that have spread or not responded to standard treatments. The drug blocks an enzyme (SCD1) that some cancers need to grow. The main goals are to find a safe dose and check for si…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 26, 2026 04:04 UTC
-
New hope for liver cancer: first human trial of AU409 begins
Disease control Recruiting nowThis early-stage trial tests a new drug called AU409 in about 36 adults with advanced liver cancer or other cancers that have spread to the liver. The main goals are to find the safest dose and see if the drug can shrink tumors or stop them from growing. Participants must have tr…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Disease control
Last updated May 26, 2026 04:03 UTC
-
New hope for kids with relapsed cancers: CBL0137 trial launches
Disease control Recruiting nowThis study tests a drug called CBL0137 in children and young adults (ages 1 to 21) whose solid tumors, brain tumors, or lymphoma have returned or stopped responding to treatment. The goal is to find the safest dose and see if the drug can shrink tumors by blocking signals that he…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated May 26, 2026 03:57 UTC
-
New hope for young cancer patients: experimental combo targets treatment-resistant tumors
Disease control Recruiting nowThis study tests a new drug combination (DT2216 plus irinotecan) in children, teens, and young adults whose solid tumors have returned or not responded to treatment. The goal is to find the safest dose and see if the combination can shrink tumors. The study includes a special gro…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated May 26, 2026 03:55 UTC
-
New drug TAK-243 targets cancer cells in early safety trial
Disease control Recruiting nowThis early-phase study tests the safety and best dose of TAK-243, a drug that blocks a key enzyme cancer cells need to grow. About 95 adults with advanced solid tumors or lymphoma who have tried other treatments will receive TAK-243. The goal is to find side effects and the right…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 03:52 UTC
-
Engineered immune cells take on Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase trial tests a new treatment for people with advanced melanoma or other solid tumors that have spread. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The goal is to find a safe dose and see if t…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: Anusha Kalbasi • Aim: Disease control
Last updated May 18, 2026 12:13 UTC
-
New hope for tough cancers: first human trial of AOH1996 begins
Disease control Recruiting nowThis study is for people with solid tumors (like lung, ovarian, or pancreatic cancer) that have stopped responding to standard treatments. It tests a new drug called AOH1996, which works by blocking certain enzymes that cancer cells need to grow. The main goals are to find the be…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 18, 2026 12:04 UTC